Belimumab and antimalarials combined against renal flares in patients treated for extra-renal systemic lupus erythematosus: results from 4 phase III clinical trials
Rheumatology (Oxford) 2023;63(2):338–48 doi: 10.1093/rheumatology/kead253
The protection conferred from belimumab against renal flare development in patients treated for extra-renal SLE appears enhanced when administered along with antimalarials (AMA).
The treatment armamentarium for LN includes AMA, which are also recommended by both EULAR and EULAR/ERA–EDTA. Yet current studies addressing the effect of AMA on preventing renal flares are scarce and conflicting. To help address this, Gomez, et al. carried out a post-hoc analysis of four RCTs of belimumab, to determine the effect of the use of AMA plus different doses and pharmaceutical forms of belimumab on preventing renal flares in patients with SLE treated for extra-renal disease.
